Antioxidant and anti-apoptotic activity of Vasoactive Intestinal Peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum

Journal of Molecular Neuroscience

Volumn 46, Issue 1, 2012, Pages 51-57

  Tunçel, Neşe ^c   Korkmaz, Orhan Tansel ^a,b,c   Tekin, Neslihan ^c   Şener, Erol ^d   Akyüz, Fahrettin ^c   Inal, Mine ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^d ANADOLU UNIVERSITY   (Turkey)

Author keywords

6 OHDA; DNA fragmentation; Nitric oxide; Oxidative damage; Parkinson's disease; Vasoactive intestinal peptide

Indexed keywords

CATALASE; MALONALDEHYDE; NITRIC OXIDE; OXIDOPAMINE; SUPEROXIDE DISMUTASE; VASOACTIVE INTESTINAL POLYPEPTIDE; ANTIOXIDANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN HOMOGENATE; BRAIN TISSUE; CAPILLARY ELECTROPHORESIS; CELL ISOLATION; CONTROLLED STUDY; CORPUS STRIATUM; DNA FRAGMENTATION; ENZYME ACTIVITY; LIPID PEROXIDATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; SHAM PROCEDURE; SPECTROPHOTOMETER; FEMALE; MALE;

RATTUS;

EID: 84858866417     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-011-9618-z     Document Type: Article

References (58)

1. Adibhatla RM, Hatcher JF (2010) Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Sign 12(1):125-169
2. Ang ET, Tai YK, Lo SQ et al (2010) Neurodegenerative diseases: exercising toward neurogenesis and neuroregeneration. Front Aging Neurosci 2(25):1-8
3. Atroshi F, Rizzo A, Biese I et al (1999) Fumonisin B-1-induced DNA damage in rat liver and spleen: Effects of pretreatment with coenzyme Q(10), L-carnitine, alpha-tocopherol and selenium. Pharmacol Res 40(6):459-467
4. Barthwal MK, Srivastava N, Shukla R et al (1999) Polymorphonuclear leukocyte nitrite content and antioxidant enzymes in Parkinson's disease patients. Acta Neurol Scand 100(5):300-304 (Pubitemid 29482553)
5. Berisha H, Foda HD, Sakakibara H et al (1990) Vasoactive intestinal peptide prevents lug injury due to xanthine/xanthine oxidase. Am J Physiol 259:L151-L155 (Pubitemid 20257247)
6. Berisha HI, Pakbaz H, Absood A et al (1994) Nitric-oxide as a mediator of oxidant lung injury due to paraquat. Proc Natl Acad Sci USA 91(16):7445-7449 (Pubitemid 24238200)
7. Beutler E (1985) Red cell metabolism. A manual of biochemical methods, 3rd edn. Grune-Stratton, New York
8. Bové J, Prou D, Perier C et al (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2(3):484-494 (Pubitemid 41444882)
9. Burton K (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62:315-323
10. Can C, Töre F, Tunçel N et al (2004) Protective effect of vasoactive intestinal peptide on testicular torsion-detorsion injury: association with heparin-containing mast cells. Urology 63:195-200 (Pubitemid 38147592)
11. Casetta I, Govoni V, Granieri E (2005) Oxidative stress, antioxidants and neurodegenerative diseases. Curr Pharm Design 11 (16):2033-2052 (Pubitemid 40766840)
12. Cohn CA, Fisher SC, Brownawell BJ et al (2010) Adenine oxidation by pyrite-generated hydroxyl radicals. Geochem T 11(2)
13. Collins JA, Schandl CA, Young KK et al (1997) Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem 45(7):923-934 (Pubitemid 27284016)
14. Delgado M, Ganea D (2003a) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 17(3):944-953
15. Delgado M, Ganea D (2003b) Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J 17 (11):1922-1930
16. Dexter DT, Jenner P, Schapira AHV et al (1992) Alterations in levels of iron, ferritin, and other trace-metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol 32(suppl S): S94-S100
17. Dogan P, Yildiz K, Mirza M (2000) Erythrocyte antioxidant enzymes and plasma ceruloplasmin levels in patients with Parkinson's disease. Period Biol 102(4):437-440
18. Dogrukol-Ak D, Banks WA, Tuncel N et al (2003) Passage of vasoactive intestinal peptide across the blood-brain barrier. Peptides 24(3):437-444 (Pubitemid 36561216)
19. Ebadi M, Sharma SK (2003) Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Sign 5(3):319-335 (Pubitemid 36793015)
20. Ebadi M, Brown-Borg H, Ren J et al (2006) Therapeutic efficacy of Selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 7(11):1513-1529 (Pubitemid 44718309)
21. Gomariz RP, Martinez C, Abad C et al (2001) Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Design 7 (2):89-111 (Pubitemid 32409709)
22. Gomes MZ, Del Bel EA (2003) Effects of electrolytic and 6-hydroxydopamine lesions of rat nigrostriatal pathway on nitric oxide synthase and nicotinamide adenine dinucleotide phosphate diaphorase. Brain Res Bull 62(2):107-115 (Pubitemid 37443656)
23. Gonzalez-Rey E, Chorny A, Fernandez-Martin A et al (2005) Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. Expert Opin Ther Tar 9(5):923-929 (Pubitemid 41488830)
24. Hirayama K, Yasutake A (1998) Free radicals and trace elements. J Trace Elem Exp Med 11(2-3):209-217 (Pubitemid 28344710)
25. Jenner P (1993) Altered mitochondrial-function, iron-metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand 87 (suppl 146):6-13
26. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47(6, suppl 3):S161-S170 (Pubitemid 26422582)
27. Kalfin R, Maulik N, Engelman RM et al (1993) Protective role of intracoronary VIP in ischemic and reperfused myocardium. J Pharmacol Exp Ther 268:952-968
28. Kalonia H, Kumar P, Kumar A et al (2010) Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats. Neurotoxicology 31(2):195-203
29. Khan MM, Ahmad A, Ishrat T et al (2010) Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res 1328:139-151
30. Kingsley GR (1942) The direct biuret method for the determination of serum proteins as applied to photoelectric and visual colorimetry. J Lab Clin Med 27:840-846
31. Kiss JP, Hennings ECP, Zsilla G et al (1999) A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum. Neurochem Int 34(4):345-350 (Pubitemid 29307800)
32. Kiss JP, Zsilla G, Vizi ES (2004) Inhibitory effect of nitric oxide on dopamine transporters: interneuronal communication without receptors. Neurochem Int 45(4):485-489 (Pubitemid 38739475)
33. Korkmaz OT, Tuncel N, Oncu EM et al (2010) Vasoactive intestinal peptide (VIP) treatment Of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells. J Mol Neurosci 41 (2):278-287
34. Kurosawa M, Ishizuka T (1993) Inhibitory effects of vasoactive- intestinal- peptide on superoxide anion formation by n-formyl- methionyl-leucyl-phenylalanine-activated inflammatory cells-in vitro. Int Arch Allergy Immunol 100:28-34 (Pubitemid 23067865)
35. Liu B (2006) Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J 8(3):E606-E621
36. Maharaj DS, Saravanan KS, Maharaj H et al (2004) Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 44 (5):355-360 (Pubitemid 37485867)
37. Miller RL, James-Kracke M, Sun GY et al (2009) Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34(1):55-65
38. Misra RB, Misa PH (1990) Vasoactive intestinal peptide, a singlet oxygen quencher. J Biol Chem 265:15371-15374
39. Nikam S, Nikam P, Ahaley SK (2009) Role of free radical and antioxidant imbalance in pathogenesis Parkinson's disease. Biomed Res-India 20(1):55-58
40. Offen D, Sherki Y, Melamed E et al (2000) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 854(1-2):257-262 (Pubitemid 30067687)
41. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358 (Pubitemid 9194347)
42. Pakbaz H, Berisha H, Foda D (1994) Vasoactive intestinal peptide and related peptides: a new class of anti-inflammatory agents? In: Rosselin G (ed) International symposium on VIP PACAP and related regulatory peptide. World Scientific, Singapore, pp 597-605
43. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates. Academic, New York
44. Said SI (1994) VIP and nitric-oxide - physiological cotransmitters with antagonistic roles in inflammation. Biomed Res-Tokyo 15 (suppl 2):79-84
45. Said SI (2000) The Viktor Mutt Memorial Lecture - Protection by VIP and related peptides against cell death and tissue injury. Ann NY Acad Sci 921:264-274
46. Said SI, Berishka HI, Pakbaz H (1995) NMDA receptors outside the central nervous system: activation causes acute lung injury that is mediated bye nitric oxide synthesis and prevented by vasoactive intestinal peptide. Neuroscience 65(4):493-496
47. Said SI, Berishka HI, Pakbaz H (1996) Excitotoxicity in the lung: N-methyl- D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase. Proc Natl Acad Sci USA 93(10):4688-4692
48. Schober A (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318 (1):215-224
49. Serra JA, Dominguez RO, de Lustig ES et al (2001) Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J Neural Transm 108(10):1135-1148 (Pubitemid 33022763)
50. Thomas B, Saravanan KS, Mohanakumar KP (2008) In vitro and in vivo evidences that antioxidant action contributes to the neuro-protective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7- nitroindazole. Neurochem Int 52(6):990-1001
51. Tuncel N, Erden S, Uzuner K et al (1997) Ischemic-reperfused rat skeletal muscle: the effect of vasoactive intestinal peptide (VIP) on the contractile force, oxygenation and antioxidant enzyme system. Peptides 18:269-275 (Pubitemid 27224392)
52. Tuncel M, Dogrukol-Ak D, Erkasap N (2001) Modified method for capillary electrophoresis to determine nitric oxide correlated nitrate in tissue homogenates. J Chromatogr B 751(2):257-263 (Pubitemid 32126313)
53. Tunçel N, Başmak H, Uzuner K et al (1996) Protection of rat retina from ischemia-reperfusion injury by vasoactive intestinal peptide (VIP): the effect of VIP on lipid peroxidation and antioxidant enzyme activity of retina and choroid. Ann NY Acad Sci 805:489-498 (Pubitemid 27058046)
54. Tunçel N, Erkasap N, Sahinturk Vet al (1998) The protective effect of vasoactive intestinal peptide (VIP) on stress-induced gastric ulceration in rats. Ann NY Acad Sci 865:309-322 (Pubitemid 29047840)
55. Tunçel N, Sener E, Cerit C et al (2005) Brain mast cells and therapeutic potential of vasoactive intestinal peptide in aParkinson's disease model in rats: brain microdialysis, behavior, and microscopy. Peptides 26:827-836 (Pubitemid 40461664)
56. Uzuner K, Tuncel N, Aydin Y et al (1995) The effect of vasoactive-intestinal- peptide (VIP) on superoxide-dismutase and catalase activities in renal tissues of rats exposed to hemorrhagic ischemia-reperfusion. Peptides 16(5):911-915
57. Winterborn CC, Hawkins RE, Brain M et al (1975) The estimation of red cell superoxide dismutase activity. J Lab Clin Med 85:337-341
58. Zhou ZD, Lim TM (2009) Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. Free Radical Res 43(4):417-U17